Diseño térmico preliminar del Instrumento PHI de Solar Orbiter

En este trabajo se describe el subsistema de control térmico de PHI y se presentan las predicciones de temperaturas obtenidas para los distintos casos de carga. Debido a la naturaleza de la órbita seguida por el satélite en el cual PHI va embarcado (Solar Orbiter), el ambiente en el cual va a tener que operar PHI será muy exigente, convirtiendo el diseño térmico en un auténtico desafío. Los resultados obtenidos muestran la viabilidad de PHI desde el punto de vista térmico, aunque indiscutiblemente el instrumento va a operar en un entorno térmico muy hostil

Thermal behaviour of Sunrise, a balloon-borne solar Telescope

Sunrise is a solar telescope, successfully flown in June 2009 with a long duration balloon from the Swedish Space Corporation Esrange launch site. The design of the thermal control of SUNRISE was quite critical because of the sensitivity to temperature of the optomechanical devices and the electronics. These problems got more complicated due the size and high power dissipation of the system. A detailed thermal mathematical model of SUNRISE was set up to predict temperatures. In this communication the thermal behaviour of SUNRISE during flight is presented. Flight temperatures of some devices are presented and analysed. The measured data have been compared with the predictions given by the thermal mathematical models. The main discrepancies between flight data and the temperatures predicted by the models have been identified. This allows thermal engineers to improve the knowledge of the thermal behaviour of the system for future missions

Vibrations loads in the process of designing scientific spacecraft payloads

Scientific missions constitute fundamental cornerstones of space agencies such as ESA and NASA. Modern astronomy could not be understood without the data provided by these missions. Scientists need to design very carefully onboard instruments. Payloads have to survive the crucial launch moment and later perform well in the really harsh space environ-ment. It is very important that the instrument conceptual idea can be engineered to sustain all those load

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.

PURPOSE: As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19-free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS: This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19-free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS: Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19-free surgical pathways. Patients who underwent surgery within COVID-19-free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19-free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score-matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19-free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION: Within available resources, dedicated COVID-19-free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Diseño preliminar térmico y estructural del instrumento NOMAD de ExoMars

El vehículo espacial ExoMarsOrbiter, llamado Exomars Trace Gas Orbiter (EMTGO), se encuadra en una misión de la ESA/NASA, contribuyendo a las ambiciones europeas de misiones de exploración futura, según lo establecido en la declaración Aurora. Los objetivos del programa ExoMars dan continuidad a los esfuerzos de cooperación con la NASA para enviar una misión de retorno de una muestra de Marte en las siguientes décadas. Están prevista s dos misiones dentro del programa ExoMars, una para 2016 y otra para 2018. NOMAD (solar occultation in the infra red and Nadir and Occultation for MArs Discovery) es un espectrómetro de alta resolución en el infrarrojo - visible - ultravioleta, observando en las franjas de 0.2 - 0.65 y 2.3 - 4.2 μm, para la inspección de la atmósfera de Marte. Dispone de tres canales (LNO, SO y UVIS) que operarán según tres modos distintos (ocultación solar, limbo y nadir). NOMAD es un instrumento con una masa de 29.9 kg que está montado sobre la bandeja superior exterior, en la cara fría del vehículo, y debe estar fuertemente desacoplado del mismo desde un punto de vista térmico (con una conductancia total máxima de 0.02 W/K). Este desacoplamiento dificulta el diseño estructural de la unión con el vehículo. El diseño térmico debe estar capacitado además para evacuar el calor disipado internamente y las cargas exteriores, utilizando únicamente métodos de control térmico pasivos. Un requisito térmico adicional es el que impone e l espectrómetro del canal LNO, que es una caja interior a NOMAD que debe ser enfriada a - 100º C. Con el objeto de cumplir estos requisitos, se disponen dos radiadores: un radiador ‘general’ para mantener al conjunto del instrumento a una temperatura semejante a la ambiente terrestre, y un radiador multietapa en “V” para enfriar la sección del LNO a - 100º C. Éste último consiste en 4 etapas con placas delgadas, que disponen de una combinación de regiones de alta emisividad y otras de alta reflectividad, para evacuar el calor entre etapas. Además, se ha de alcanzar un compromiso entre la rigidez del radiador y la masa del mismo para disminuir la masa del radiador, las placas delgadas deben ser rigidizadas estructuralmente. Tanto su diseño térmico como el estructural representan un reto tecnológico, debido a su escasa presencia en misiones anteriores. El modelo geométrico y los modelos matemáticos térmico s y estructural es se han construido siguiendo los estándares de la ESA. Esto es, la metodología utilizada ha sido la de efectuar primero un diseño conceptual preliminar, para posteriormente desarrollar un modelo térmico y otro estructural a nivel instrumento, con el software ESATAN y NASTRAN, ambos indicados por la ESA. Los resultados muestran la viabilidad de NOMAD desde un punto de vista térmico y estructural

The on-ground data reduction and calibration pipeline for SO/PHI-HRT

The ESA/NASA Solar Orbiter space mission has been successfully launched in February 2020. Onboard is the Polarimetric and Helioseismic Imager (SO/PHI), which has two telescopes, a High Resolution Telescope (HRT) and the Full Disc Telescope (FDT). The instrument is designed to infer the photospheric magnetic field and line-of-sight velocity through differential imaging of the polarised light emitted by the Sun. It calculates the full Stokes vector at 6 wavelength positions at the Fe I 617.3 nm absorption line. Due to telemetry constraints, the instrument nominally processes these Stokes profiles onboard, however when telemetry is available, the raw images are downlinked and reduced on ground. Here the architecture of the on-ground pipeline for HRT is presented, which also offers additional corrections not currently available on board the instrument. The pipeline can reduce raw images to the full Stokes vector with a polarimetric sensitivity of 10−3⋅Ic or better.Sección Deptal. de Óptica (Óptica)Fac. de Óptica y OptometríaTRUEBMWi - Bundesministerium für Wirtschaft und Energie (Alemania)MPG - Max-Planck-Gesellschaft (Alemania)Ministerio de Ciencia e Innovación de España - MCIUInstituto de Astrofísica de Andalucía - CSIC (España)CNES - Centre National d'études spatiales (Francia)Fondos FEDERAgencia Estatal de Investigación - AEI (ESpaña)pu

Metis: the Solar Orbiter visible light and ultraviolet coronal imager

Aims. Metis is the first solar coronagraph designed for a space mission and is capable of performing simultaneous imaging of the off-limb solar corona in both visible and UV light. The observations obtained with Metis aboard the Solar Orbiter ESA-NASA observatory will enable us to diagnose, with unprecedented temporal coverage and spatial resolution, the structures and dynamics of the full corona in a square field of view (FoV) of ±2.9° in width, with an inner circular FoV at 1.6°, thus spanning the solar atmosphere from 1.7 R⊙ to about 9 R⊙, owing to the eccentricity of the spacecraft orbit. Due to the uniqueness of the Solar Orbiter mission profile, Metis will be able to observe the solar corona from a close (0.28 AU, at the closest perihelion) vantage point, achieving increasing out-of-ecliptic views with the increase of the orbit inclination over time. Moreover, observations near perihelion, during the phase of lower rotational velocity of the solar surface relative to the spacecraft, allow longer-term studies of the off-limb coronal features, thus finally disentangling their intrinsic evolution from effects due to solar rotation. Methods. Thanks to a novel occultation design and a combination of a UV interference coating of the mirrors and a spectral bandpass filter, Metis images the solar corona simultaneously in the visible light band, between 580 and 640 nm, and in the UV H 

Combined dark matter searches towards dwarf spheroidal galaxies with Fermi-LAT, HAWC, H.E.S.S., MAGIC, and VERITAS

Cosmological and astrophysical observations suggest that 85\% of the total matter of the Universe is made of Dark Matter (DM). However, its nature remains one of the most challenging and fundamental open questions of particle physics. Assuming particle DM, this exotic form of matter cannot consist of Standard Model (SM) particles. Many models have been developed to attempt unraveling the nature of DM such as Weakly Interacting Massive Particles (WIMPs), the most favored particle candidates. WIMP annihilations and decay could produce SM particles which in turn hadronize and decay to give SM secondaries such as high energy $\gamma$ rays. In the framework of indirect DM search, observations of promising targets are used to search for signatures of DM annihilation. Among these, the dwarf spheroidal galaxies (dSphs) are commonly favored owing to their expected high DM content and negligible astrophysical background. In this work, we present the very first combination of 20 dSph observations, performed by the Fermi-LAT, HAWC, H.E.S.S., MAGIC, and VERITAS collaborations in order to maximize the sensitivity of DM searches and improve the current results. We use a joint maximum likelihood approach combining each experiment's individual analysis to derive more constraining upper limits on the WIMP DM self-annihilation cross-section as a function of DM particle mass. We present new DM constraints over the widest mass range ever reported, extending from 5 GeV to 100 TeV thanks to the combination of these five different $\gamma$-ray instruments